In this OncLive Peer Exchange series, a panel of experts discusses the latest advancements in the management of gynecological cancers, highlighting updates from ESMO 2024, including treatment paradigms for advanced ovarian, cervical, and endometrial cancers, biomarker testing strategies, and emerging therapies such as antibody-drug conjugates.
EP. 1: Approaching Biomarker Testing and Frontline Maintenance Therapy for Advanced Ovarian Cancer
September 30th 2024Panelists discuss frontline maintenance therapies for advanced ovarian cancer, focusing on the impact of BRCA and HRD statuses on treatment selection and the choice between combination therapy (PARPi + bev) and monotherapy.
EP. 2: Key Findings from the PRIMA Trial: Niraparib in 1L Maintenance for Advanced Ovarian Cancer
September 30th 2024Panelists discuss optimal durations for PARP inhibitor maintenance therapy in ovarian cancer, exploring how long patients are typically kept on PARPi in both first-line and second-line maintenance settings.